Compass Pathways soars on second Phase 3 depression hitnews2026-02-17T15:38:26+00:00February 17th, 2026|Endpoints News|
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sinknews2026-02-17T12:05:11+00:00February 17th, 2026|Endpoints News|
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapynews2026-02-17T11:03:37+00:00February 17th, 2026|Endpoints News|
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and morenews2026-02-14T11:00:17+00:00February 14th, 2026|Endpoints News|
Gilead gets cancer drug from China-based Genhouse for $80M upfrontnews2026-02-13T18:53:40+00:00February 13th, 2026|Endpoints News|
Pentagon adds, then withdraws, WuXi AppTec to Chinese military listnews2026-02-13T18:48:38+00:00February 13th, 2026|Endpoints News|
Lilly appeals retatrutide classification ruling in case that could impact compoundersnews2026-02-13T17:31:04+00:00February 13th, 2026|Endpoints News|
Epigenetic editing startup Moonwalk shifts focus to siRNA for obesitynews2026-02-13T16:14:41+00:00February 13th, 2026|Endpoints News|
Lundbeck’s migraine prevention drug succeeds in Phase 2, advancing new therapy classnews2026-02-13T15:55:35+00:00February 13th, 2026|Endpoints News|
Moderna’s flu shot dilemma muddies 2028 break-even guidancenews2026-02-13T15:55:13+00:00February 13th, 2026|Endpoints News|
